EndoCDx® sharply increases detection of Barrett’s Esophagus (BE) and Esophageal Dysplasia (ED) in 2 recently published studies:
In Patients Being Screened for BE and ED, EndoCDx® Increased the Detection of BE by 40% and ED by 88%
In a High-Risk Barrett’s Esophagus Surveillance Population, EndoCDx® Increased the Detection of ED by 42%
EndoCDx®: Obtaining a Laryngeal Biopsy Specimen in Unsedated Patients in the Office Setting Is Now Possible and Easy to Perform
The EndoCDx brush biopsy is an office-based sampling of laryngeal tissue, without the need for general anesthesia. The brush biopsy achieves a complete transepithelial sample and the specimen is analyzed with the aid of a specialized neural network computer system
OralCDx®: An accurate and non-invasive biopsy to evaluate common oral lesions to rule out dysplasia or cancer.
OralCDx is a noninvasive, painless, practical and accurate biopsy method of testing suspicious oral lesions. The OralCDx diagnostic brush biopsy, which obtains a full-thickness specimen, is used to identify dysplasia and early stage oral cancer among common red and/or white lesions. The brush biopsy requires no topical or local anesthetic, and causes minimal or no bleeding or pain. The analysis of the OralCDx specimens is aided with a highly specialized neural network-based image processing system.
OralCDx®
OralCDx® is a non-invasive full thickness biopsy that can be used to rule out oral dysplasia or cancer.
EndoCDx® EGD
EndoCDx® EGD has been demonstrated to significantly increase the detection of Barrett's esophagus and esophageal dysplasia.
EndoCDx® TNE
EndoCDx® TNE is a revolutionary procedure that helps increase the reliability of transnasal esophagoscopy (TNE) in evaluating esophageal disease.
EndoCDx® LP
EndoCDx® LP is a new in-office procedure for otolaryngologists used to identify dysplasia and early stage cancer of the larynx, pharynx, and surrounding tissues.
© 2012 CDx Diagnostics D/B/A Oral Cancer Prevention International, Inc.